Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Pharmaceutical Statistics|June 10, 2025
Applying Bias Correction Methods to Build Hybrid Controls Using Real-World Patients for a Phase IIb Randomized Controlled Trial of Baricitinib for Rheumatoid ArthritisHeather J Litman, Kristin M Sheffield, Oksana Pugach, et al.
Advances in Therapy|March 30, 2023
Characteristics and Outcomes in Cases of US Male Patients with Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical PracticeAlistair Ring, Meghan Karuturi, Emily Nash Smyth, et al.
Drugs - Real World Outcomes|September 29, 2023
Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2- Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical PracticeAlistair Ring, Meghan Karuturi, Emily Nash Smyth, et al.
Breast Cancer Research and Treatment|June 13, 2023
Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2- MBC in the real worldMegan Kruse, Emily Nash Smyth, Lee Bowman, et al.
Annals of Surgery|September 5, 2014
Surgeon and Facility Variation in the Use of Minimally Invasive Breast Biopsy in TexasNina P Tamirisa, Kristin M Sheffield, Abhishek D Parmar, et al.
Annals of Surgery|July 30, 2014
PREOP-Gallstones: A Prognostic Nomogram for the Management of Symptomatic Cholelithiasis in Older PatientsAbhishek D Parmar, Kristin M Sheffield, Deepak Adhikari, et al.
Current Medical Research and Opinion|May 10, 2022
Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community settingGregory L Price, Lavanya Sudharshan, Paula Ryan, et al.
BMJ Open|June 16, 2018
Perceptions of overdetection of breast cancer among women 70 years of age and older in the USA: a mixed-methods analysisMonique R Pappadis, Robert J Volk, Shilpa Krishnan, et al.
Cancer Treatment and Research Communications|August 5, 2020
KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysisRebecca Ellen Goulding, Matthew Chenoweth, Gebra Cuyun Carter, et al.
Current Medical Research and Opinion|May 10, 2021
Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2- metastatic breast cancerGebra Cuyun Carter, Kristin M Sheffield, Anala Gossai, et al.
Pageof 7